Application of nanomaterials in tumor imaging diagnosis / 肿瘤

Malignant tumors have become one of the major diseases that seriously endanger human life.Early diagnosis and treatment can greatly improve the survival rate of patients.Imaging examinations based on fluorescence imaging,CT,photoacoustic imaging,MRI,and PET have been widely studied and applied in the diagnosis of tumors.However,early cancerous tissue and normal tissue have similar imaging signals,which is difficult to be accurately distinguished by conventional imaging.With the development and cross integration of physics,materials science,biology,and medicine,nanomaterials have shown broad application prospects in the diagnosis and treatment of diseases due to their unique physical and chemical properties.The enhanced permeability and retention effect in solid tumor,and the easy modification properties of nanomaterials allow them to accurately"recognize"tumor and accelerate its enrichment at the tumor site;the imaging characteristics allow them to be used as contrast agents to enhance the signal intensity of the tumor site;their responsiveness mechanism can also allow them to distinguish normal from cancerous cells according to the microenvironment in tumor cells.In addition,multimodality imaging based on nanomaterials can compensate for the shortcomings of single modality imaging and achieve real-time and omnidirectional imaging of tumors.With multiple functions integrated,nanomaterials are expected to enhance the imaging signals of early cancerous sites,improve signal-to-noise ratio,and achieve early diagnosis of tumors.

Research on the biological significance of the LncRNA LOC 100288637 expression differences in primary hepatic carcinoma and the related mechanism / 重庆医学

Objective To explore the expression differences of long noncoding RNA (LncRNA) LOC100288637 in liver canc‐er ,the effect of LOC100288637 on liver cancer cell proliferation and the relevant mechanisms .Methods Based on the analysis of the GEO database data sets GSE58043 and GSE10694 ,we found that both LOC100288637 and hsa‐miR‐101‐3p has obvious expression differences in liver cancer tissues .RNA hybrid revealed the possibility of combination between LOC 100288637 and hsa‐miR‐101‐3p;RT‐PCR was performed to measure the expression level of LOC100288637 in tissues and cells ;fluorescence in situ hybridization was used to observe LOC100288637 localization in cells ;cell proliferation was determined by CCK8 experiment after LOC100288637 siRNA knock down .The expression of LOC100288637 in cells were measured after treated with hsa‐miR‐101‐3p mimics .Results Relative quantitative expression of LOC100288637 in liver cancer tissues group was significantly higher than that in no tumor tis‐sues group (P<0 .05);relative quantitative expression of LOC100288637 in liver cancer cell lines were significantly higher than that in normal liver cell line(P<0 .05) .LOC100288637 was located in both cytoplasm and nucleus of HepG2 cells ,and mainly in cy‐toplasm .Cell proliferation vitality of HepG2 reduced after treated with LOC100288637‐siRNA(P<0 .01) .Relative quantitative ex‐pression of LOC100288637 in HepG2 reduced after treated with hsa‐miR‐101‐3p mimics ( P< 0 .05 ) .Conclusion LncRNA LOC100288637 may play an important role in liver cancer development ,it can be down regulated by hsa‐miR‐101‐3p and affect the proliferation of liver cancer cells .